Teva, Bristol-Myers Cite Bystolic Against Cancer Drug Case

By Bryan Koenig · May 22, 2024, 4:58 PM EDT

Celgene and parent Bristol-Myers Squibb pointed a New Jersey federal judge to the dismissal, recently upheld by the Second Circuit, of an antitrust suit over delayed generic competition to AbbVie's hypertension...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Letter

Case Information

Case Title

IN RE REVLIMID & THALOMID PURCHASER ANTITRUST LITIGATION

Case Number

Court

New Jersey

Nature of Suit

Anti-Trust

Date Filed

March 01, 2019

Recent Articles By Bryan

June 13, 2024
EU Makes First Ever Formal Pharma Price-Fixing Complaint
June 12, 2024
Texas Anesthesia Co. Appealing To Duck FTC Suit To 5th Circ.
June 10, 2024
Rehab Clinics Add To MultiPlan Insurance Fixing Pile-On
May 14, 2024
FTC Cleared To Sue Texas Anesthesia Co., But Not PE Firm
May 09, 2024
DOJ Task Force To Target Healthcare Monopoly, Collusion
May 07, 2024
$55M Hospital Merger Suit Deal OK'd, UHC Objection Rejected
April 04, 2024
Structure Defense Remains In FTC Hospital Case, But Not Hearing
March 27, 2024
NY AG, Others Blast Sandoz Deal 'Tax' On Future Settlements
March 25, 2024
FTC Intervenes In Teva-Amneal Row To Push Patent Delisting
March 21, 2024
Avoid Major Extension Of Merger Reach, EU High Court Urged